Insights from 2023 ESMO Asia Annual Meeting


 

ESMO Asia 2023 Insights: "Final Results of the RATIONALE-305 Study - Tislelizumab + Chemo vs. Placebo + Chemo as 1L Treatment of Advanced GC/GEJC"

132 views
January 9, 2024
Comments 0
Login to view comments. Click here to Login